News | January 07, 2026
Merck completes acquisition of Cidara Therapeutics
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Brenntag will supply Food & Nutrition customers in the United States and Canada with Lallemand’s renowned Nutrilife baking enzyme range
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Subscribe To Our Newsletter & Stay Updated
